This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia

This study has been completed.
Information provided by:
UPECLIN HC FM Botucatu Unesp Identifier:
First received: May 11, 2010
Last updated: October 29, 2010
Last verified: October 2010

Objective: To compare the clinical effectiveness and hospital costs, the initial empirical treatment, Oxacillin / Ceftriaxone and Amoxicillin / Clavulanate in children with Community Acquired Pneumonia (CAP) severe.

Methods: Clinical prospective randomized study in children aged two months to five years of age with a diagnosis of severe CAP, according to criteria of World Health Organization (WHO), admitted to the Pediatrics Ward of the Hospital of the Medical School of Botucatu- UNESP. We excluded children with comorbid disorders (primary and secondary immunodeficiency) with acute or chronic kidney disease, referred patients receiving antibiotics proposal and history of allergy to antibiotics proposed. We included 104 children who were randomized into two groups to receive: Oxacillin / Ceftriaxone IV (GCO, n = 48) and Amoxicillin / Clavulanate IV (GAA, n = 56). Patients of the GAA, after clinical improvement, has been receiving the same oral antibiotic, and maintaining clinical stability, were discharged from hospital, the GOC received any IV treatment. The outcomes analyzed were time to clinical improvement (fever and tachypnea), duration of oxygen therapy, hospitalization time, need to expand the antimicrobial spectrum progression to pleural effusion / empyema (DP / E) and hospital costs. Treatment failure was determined by the need to expand the antimicrobial spectrum after 48 hours of hospitalization.

Condition Intervention Phase
Community-Acquired Pneumonia Drug: Amoxycillin/clavulanic acid Drug: ceftriaxone/oxacillin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Care Provider)
Primary Purpose: Treatment
Official Title: COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study

Resource links provided by NLM:

Further study details as provided by UPECLIN HC FM Botucatu Unesp:

Primary Outcome Measures:
  • length of stay at pediatric ward. [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • need for broadening the spectrum antimicrobials. [ Time Frame: 3 years ]

Enrollment: 104
Study Start Date: April 2005
Study Completion Date: April 2009
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: amoxicillin/clavulanic acid
patients who received amoxicillin/clavulanic acid
Drug: Amoxycillin/clavulanic acid
100mg/Kg/day/10 days.
Active Comparator: ceftriaxone/oxacillin Drug: ceftriaxone/oxacillin
75 mg/Kg/day/10 days.

Detailed Description:

eligibility: Children aged two months to five years with diagnosis of severe community acquired pneumonia, requiring hospitalization.

Outcomes measures: time to clinical improvement (respiratory rate and fever), duration of oxygen therapy, length of stay in the Division of Pediatrics, evolution with clinical complications, need for broadening the spectrum antimicrobials.


Ages Eligible for Study:   2 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • children aged from 2 months to 5 years
  • children diagnosed with severe community-acquired pneumonia, who require hospitalization.

Exclusion Criteria:

  • chronical diseases
  • severe comorbidities
  • children admitted at PICU
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01166932

Cristiane Franco Ribeiro
Botucatu, Sao Paulo, Brazil, 18.618-970
Sponsors and Collaborators
UPECLIN HC FM Botucatu Unesp
Principal Investigator: Cristiane F Ribeiro, MD UNESP - Botucatu Medical School
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jose Roberto Fioretto, UNESP HC FM Botucatu Unesp Identifier: NCT01166932     History of Changes
Other Study ID Numbers: upeclin/HC/FMB-Unesp-44
Study First Received: May 11, 2010
Last Updated: October 29, 2010

Keywords provided by UPECLIN HC FM Botucatu Unesp:

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Clavulanic Acids
Clavulanic Acid
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
beta-Lactamase Inhibitors processed this record on June 22, 2017